Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-ascending-dose study of NPT189 in healthy volunteers
NL-OMON46311Phase 1Active, not recruiting
- Sponsor
- Proclara Biosciences
- Start
- Jul 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyloidosis comparing NPT189 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jul 2018; status: active, not recruiting.
02
Drugs
PCS-01
03
Conditions
amyloidosis
Beyond the preview
Go deeper on NL-OMON46311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46311.